Last reviewed 2026-04-19 · How we verify

mRNA-1083 Composition 1 Dose A Lot A

ModernaTX, Inc. · Phase 2 active Biologic

mRNA-1083 Composition 1 Dose A Lot A is a Biologic drug developed by ModernaTX, Inc.. It is currently in Phase 2 development.

At a glance

Generic name	mRNA-1083 Composition 1 Dose A Lot A
Sponsor	ModernaTX, Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

mRNA-1083 Composition 1 Dose A Lot A CI brief — competitive landscape report
mRNA-1083 Composition 1 Dose A Lot A updates RSS · CI watch RSS
ModernaTX, Inc. portfolio CI

Frequently asked questions about mRNA-1083 Composition 1 Dose A Lot A

What is mRNA-1083 Composition 1 Dose A Lot A?

mRNA-1083 Composition 1 Dose A Lot A is a Biologic drug developed by ModernaTX, Inc..

Who makes mRNA-1083 Composition 1 Dose A Lot A?

mRNA-1083 Composition 1 Dose A Lot A is developed by ModernaTX, Inc. (see full ModernaTX, Inc. pipeline at /company/modernatx-inc).

What development phase is mRNA-1083 Composition 1 Dose A Lot A in?

mRNA-1083 Composition 1 Dose A Lot A is in Phase 2.

Manufacturer: ModernaTX, Inc. — full pipeline